Lung cancer is the leading cause of death from cancer in the United States. Better understanding of oncogenes and tumor suppressor genes involved in lung cancer hold the promise of improving clinical care of afflicted patients.
Prior work from our group has focused on transcription factors involved in lung cancer and mechanisms of sensitivity/resistance of oncogene kinases (such as EGFR, ALK, KRAS, ROS1, RET among others) to tyrosine kinase inhibitors in non-small-cell lung cancer.
Our group is also part of the clinical research effort at DFHCC, with a focus in non-small-cell lung cancer. We are part of the NIH/NCI-funded SPORE in Lung Cancer at DFHCC.
(co-investigators at BIDMC: Susumu Kobayashi, MD, PhD, Daniel G. Tenen, MD; Mark Huberman, MD and Deepa Rangachari, MD)
(co-investigators at DFCI: Pasi Janne, MD, PhD; Geoffrey Oxnard, MD; David Jackman, MD; Michael Eck, MD, PhD; Peter Hammerman, MD, PhD; Matthew Meyerson, MD, PhD; Kwok-Kin Wong, MD, PhD; and Bruce Johnson, MD)
(co-investigators at MGH: Lecia V. Sequist, MD, MPH; Alice Shaw, MD, PhD and Jeffrey Engelman, MD, PhD)